Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece.
Kastritis E, Ntanasis-Stathopoulos I, Theodorakakou F, Migkou M, Roussou M, Malandrakis P, Kanellias N, Eleutherakis-Papaiakovou E, Fotiou D, Spiliopoulou V, Gavriatopoulou M, Patel S, Majer I, Boukis C, Fetani A, Dimopoulos MA, Terpos E. Kastritis E, et al. Among authors: roussou m. Clin Lymphoma Myeloma Leuk. 2024 Mar 19:S2152-2650(24)00110-1. doi: 10.1016/j.clml.2024.03.003. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38616479 Free article.
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: roussou m. Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059. Clin Lymphoma Myeloma. 2009. PMID: 19717380
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E. Dimopoulos MA, et al. Among authors: roussou m. Leukemia. 2010 Oct;24(10):1769-78. doi: 10.1038/leu.2010.175. Epub 2010 Aug 26. Leukemia. 2010. PMID: 20739955
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma.
Papassotiriou GP, Kastritis E, Gkotzamanidou M, Christoulas D, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Roussou M, Margeli A, Papassotiriou I, Dimopoulos MA, Terpos E. Papassotiriou GP, et al. Among authors: roussou m. Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):29-35. doi: 10.1016/j.clml.2015.10.003. Epub 2015 Nov 3. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26632077
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
Eleutherakis-Papaiakovou E, Kastritis E, Gavriatopoulou M, Christoulas D, Roussou M, Ntanasis-Stathopoulos I, Kanellias N, Papatheodorou A, Dimopoulos MA, Terpos E. Eleutherakis-Papaiakovou E, et al. Among authors: roussou m. Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):431-437. doi: 10.1016/j.clml.2018.03.010. Epub 2018 Mar 31. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29685422
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Papasotiriou I, Fotiou D, Migkou M, Roussou M, Kanellias N, Ziogas D, Dialoupi I, Eleutherakis Papaiakovou E, Kastritis E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: roussou m. Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):23-28. doi: 10.1016/j.clml.2018.07.294. Epub 2018 Aug 23. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30224328
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients.
Gavriatopoulou M, Fotiou D, Koloventzou U, Roussou M, Migkou M, Ntanasis-Stathopoulos I, Kanellias N, Ziogas DC, Panagiotidis I, Gika D, Eleutherakis-Papaiakovou E, Terpos E, Kastritis E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: roussou m. Leuk Lymphoma. 2019 Mar;60(3):619-628. doi: 10.1080/10428194.2018.1509323. Epub 2019 Jan 10. Leuk Lymphoma. 2019. PMID: 30628505
101 results